289 related articles for article (PubMed ID: 17383100)
21. Oxaliplatin in ovarian cancer.
Sessa C; ten Bokkel Huinink WW; du Bois A
Ann Oncol; 1999; 10 Suppl 1():55-7. PubMed ID: 10219454
[TBL] [Abstract][Full Text] [Related]
22. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship.
Stordal B; Pavlakis N; Davey R
Cancer Treat Rev; 2007 Dec; 33(8):688-703. PubMed ID: 17881133
[TBL] [Abstract][Full Text] [Related]
23. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
[TBL] [Abstract][Full Text] [Related]
24. The emerging role of oxaliplatin in the treatment of gastric cancer.
Zaniboni A; Meriggi F
J Chemother; 2005 Dec; 17(6):656-62. PubMed ID: 16433197
[TBL] [Abstract][Full Text] [Related]
25. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Culy CR; Clemett D; Wiseman LR
Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
[TBL] [Abstract][Full Text] [Related]
26. Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo.
Chen SJ; Kuo CC; Pan HY; Tsou TC; Yeh SC; Chang JY
Biochem Pharmacol; 2015 May; 95(1):28-37. PubMed ID: 25801007
[TBL] [Abstract][Full Text] [Related]
27. Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines.
Kashiwagi E; Izumi H; Yasuniwa Y; Baba R; Doi Y; Kidani A; Arao T; Nishio K; Naito S; Kohno K
Cancer Sci; 2011 Feb; 102(2):382-6. PubMed ID: 21087353
[TBL] [Abstract][Full Text] [Related]
28. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
[TBL] [Abstract][Full Text] [Related]
29. Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer.
Raez LE; Kobina S; Santos ES
Clin Lung Cancer; 2010 Jan; 11(1):18-24. PubMed ID: 20085863
[TBL] [Abstract][Full Text] [Related]
30. Comparative effectiveness and safety between oxaliplatin-based and cisplatin-based therapy in advanced gastric cancer: A meta-analysis of randomized controlled trials.
Huang J; Zhao Y; Xu Y; Zhu Y; Huang J; Liu Y; Zhao L; Li Z; Liu H; Wang QL; Qi X
Oncotarget; 2016 Jun; 7(23):34824-31. PubMed ID: 27166187
[TBL] [Abstract][Full Text] [Related]
31. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer.
Piccart MJ; Lamb H; Vermorken JB
Ann Oncol; 2001 Sep; 12(9):1195-203. PubMed ID: 11697824
[TBL] [Abstract][Full Text] [Related]
32. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.
Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G
Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093
[TBL] [Abstract][Full Text] [Related]
33. Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients.
Stukova M; Hall MD; Tsotsoros SD; Madigan JP; Farrell NP; Gottesman MM
J Inorg Biochem; 2015 Aug; 149():45-8. PubMed ID: 26021697
[TBL] [Abstract][Full Text] [Related]
34. New platinum antitumor complexes.
Kelland LR
Crit Rev Oncol Hematol; 1993 Dec; 15(3):191-219. PubMed ID: 8142057
[TBL] [Abstract][Full Text] [Related]
35. A better platinum-based anticancer drug yet to come?
Olszewski U; Hamilton G
Anticancer Agents Med Chem; 2010 May; 10(4):293-301. PubMed ID: 20187870
[TBL] [Abstract][Full Text] [Related]
36. Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivo.
Li S; Li C; Jin S; Liu J; Xue X; Eltahan AS; Sun J; Tan J; Dong J; Liang XJ
Biomaterials; 2017 Nov; 144():119-129. PubMed ID: 28834763
[TBL] [Abstract][Full Text] [Related]
37. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
38. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
39. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer.
Becouarn Y; Rougier P
Semin Oncol; 1998 Apr; 25(2 Suppl 5):23-31. PubMed ID: 9609105
[TBL] [Abstract][Full Text] [Related]
40. New strategies against prostate cancer--Pt(II)-based chemotherapy.
Matos CS; de Carvalho AL; Lopes RP; Marques MP
Curr Med Chem; 2012; 19(27):4678-87. PubMed ID: 22856665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
